Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model.
Journal: The Journal of clinical investigation
Published: June 16, 2026
Efficacy of Minnelide in a Next-Generation Dual-Recombinase Regulated Genetically Engineered Mouse Model of CIC::DUX4 Sarcoma.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model.
Journal: The Journal of clinical investigation
Published: November 10, 2025
Symptomatic Necrosis With Dual Immune-Checkpoint Inhibition and Radiosurgery for Brain Metastases.
Journal: JAMA network open
Published: April 09, 2025
Response to Central Boost Radiation Therapy in Unresectable Retroperitoneal Sarcoma: A Case Series.
Journal: Advances in radiation oncology
Published: April 02, 2024
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2024
Case of a CIC::DUX4 fusion gene in a vascular neoplasm extends the spectrum of CIC-rearranged sarcomas.
Journal: Journal of cutaneous pathology
Published: March 10, 2024
Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice.
Journal: Oncogene
Published: October 24, 2023
Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models.
Journal: bioRxiv : the preprint server for biology
Published: October 09, 2023
Last Updated: 09/26/2026